Invectys

Invectys Sa

Centre National De La Recherche Scientifique

Université De Franche Comte

Centre Hospitalier Régional Universitaire De Besançon

Institut Pasteur

Invectys Sas

Pierre Langlade Demoyen

Julien Caumartin

Maria Loustau

Simon Wain-Hobson

Thierry Huet

Christelle Liard

François Anna

Elodie Pliquet

Maria Wehbe

Olivier Adotevi

Magalie Dosset

Frédéric Tangy

Luis Maria Mir

Jessie Thalmensi

Christophe Calvet

Anna Kostrzak

Luis M Mir

The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G β2M-free or β2M-associated immunosuppressive isoforms respectively.

Chimeric antigen receptors against multiple HLA-G isoforms

The invention provides a nucleic acid construct comprising a sequence that encodes a human telomerase reverse transcriptase (hTERT) protein which is devoid of telomerase catalytic activity and of a nucleolar localization signal. The construct is useful triggering an immune response in a subject, against cells that overexpress telomerase, preferably dysplasia cells or tumor cells.

Telomerase encoding DNA vaccine

The present invention relates to antibodies, or antigen-binding fragments thereof, directed against human leukocyte antigen-G (HLA-G) protein and raised against an immunogenic peptide derived from the &#x3b1;3 domain of HLA-G protein. The invention further relates to the immunogenic peptide, and methods for producing said anti-HLA-G specific antibodies.

Anti HLA-G specific antibodies

The present invention relates to chimeric antigen receptors (CAR) against multiple but not all human leukocyte antigen (HLA-G) isoforms. More specifically, the invention concerns CARs that are specific for HLA-G &#x3b2;2M-free or &#x3b2;2M-associated immunosuppressive isoforms respectively.

The invention relates a recombinant measles virus plasmid capable of expressing a human telomerase reverse transcriptase (hTERT) protein fused at N-terminus with a protein enhancing addressing of the hTERT protein to proteasome. The invention further relates to a vaccine comprising said plasmid or particles rescued therefrom, and uses thereof, especially in preventing or treating a tumor in a patient.

Recombinant measles vaccine expressing hTERT

The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Universal cancer peptides derived from telomerase

The present invention provides a nucleic acid, or an immunogenic composition thereof, that comprises a sequence encoding a cat telomerase deprived of telomerase catalytic activity, or a fragment thereof. The present invention also provides methods for triggering an immune response in a cat and methods for treating or preventing a tumor in a cat using the immunogenic composition of the invention.

Cancer vaccine for cats

The present invention relates to methods for transferring a nucleic acid in vivo into skin cells wherein the nucleic acid is injected by intradermal (ID) injection and is electrically transferred into skin cells with a single pulse of a High Voltage, followed, after a defined lag time, by a single pulse of Low Voltage.

Gene electrotransfer into skin cells

The present invention provides an immunogenic composition comprising a nucleic acid that comprises a sequence encoding a dog telomerase deprived of telomerase catalytic activity, or a fragment thereof.

Cancer vaccine for dogs

The present invention relates to the use of a nucleic acid that comprises a sequence encoding an APOBEC3A protein, in preventing or treating a tumor in a patient.

Growing community of inventors

Neuilly-sur-Seine, France

Pierre Langlade Demoyen